ReviewFrontiers in pharmacology2020
Calcific Aortic Valve Disease-Natural History and Future Therapeutic Strategies.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis.Cardiovascular research · 2023Pooled it
- Balloon-Expandable Versus Self-Expandable Transcatheter Aortic Valve Implantation Devices: A Contemporary Systematic Review.Journal of clinical medicine · 2026Review
- ALOX5-Mediated LTA4 Production Enhances PLCG2/IP3 Signaling and Exacerbates Calcification in Human Aortic Valve Interstitial Cells.Acta Cardiologica Sinica · 2026Article
- Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved.International journal of molecular sciences · 2026Review
- Chemerin Activation of Toll-Like Receptor 4 Drives Mineralocorticoid Receptor-Mediated Aortic Valve Remodeling in Chronic Kidney Disease.Journal of the American Heart Association · 2026Article
- Matrix metalloproteinase activation and TNF upregulation characterize the sclerotic phase of aortic valve disease.British journal of biomedical science · 2026Article
- Potential and Future Therapeutic Applications of Eicosapentaenoic/Docosahexaenoic Acid and Probiotics in Chronic Low-Grade Inflammation.Biomedicines · 2025Review
- EP300/CREBBP induces osteogenic differentiation of valve interstitial cells by promoting the SPP1 expression in calcific aortic valve disease.Cytotechnology · 2025Article
- Reversion of aortic valve cells calcification by activation of Notch signalling via histone acetylation induction.Signal transduction and targeted therapy · 2025Article
- The interactions of Lipoprotein(a) with common cardiovascular risk factors in cardiovascular disease risk: evidence based on the UK Biobank.American journal of preventive cardiology · 2025Article
- Lipoprotein(a) and panvascular disease.Lipids in health and disease · 2025Review
- Age Differences in Aortic Stenosis.Reviews in cardiovascular medicine · 2025Review
- [The association between biological aging markers and valvular heart diseases].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Article
- Atherosclerosis, calcific aortic valve disease and mitral annular calcification: same or different?International journal of cardiology · 2025Review
- Article
- Insights into calcific aortic valve stenosis: a comprehensive overview of the disease and advancing treatment strategies.Annals of medicine and surgery (2012) · 2024Review
- Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?International journal of molecular sciences · 2024Review
- CircRNAJournal of thoracic disease · 2023Article
- Increasing baseline aortic valve peak flow velocity is associated with progression of aortic valve stenosis in osteoporosis patients-a possible link to low vitamin D status.Archives of osteoporosis · 2023Article
- Challenges of aortic valve tissue culture - maintenance of viability and extracellular matrix in the pulsatile dynamic microphysiological system.Journal of biological engineering · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcific aortic valve disease (CAVD) is the most frequent heart valve disorder. It is characterized by an active remodeling process accompanied with valve mineralization, that results in a progressive aortic valve narrowing, significant restriction of the valvular area, and impairment of blood flow.The pathophysiology of CAVD is a multifaceted process, involving genetic factors, chronic inflammation, lipid deposition, and valve mineralization. Mineralization is strictly related to the inflammatory process in which both, innate, and adaptive immunity are involved. The underlying pathophysiological pathways that go from inflammation to calcification and, finally lead to severe stenosis, remain, however, incompletely understood. Histopathological studies are limited to patients with severe CAVD and no samples are available for longitudinal studies of disease progression. Therefore, alternative routes should be explored to investigate the pathogenesis and progression of CAVD.Recently, increasing evidence suggests that epigenetic markers such as non-coding RNAs are implicated in the landscape of phenotypical changes occurring in CAVD. Furthermore, the microbiome, an essential player in several diseases, including the cardiovascular ones, has recently been linked to the inflammation process occurring in CAVD. In the present review, we analyze and discuss the CAVD pathophysiology and future therapeutic strategies, focusing on the real and putative role of inflammation, calcification, and microbiome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.